RFP
CRNX icon

Root Financial Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Root Financial Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14
Closed -$508 – 1024
2026
Q1 		$508 Buy
+14
New +$625 ﹤0.01% 2856

Other funds holding CRNX

New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Root Financial Partners's CRNX Position: Q2 2026 in Review

Root Financial Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 14 shares — an estimated $508 sold.

Root Financial Partners first reported a position in CRNX in Q1 2026 and held it in 1 quarter. The position peaked at $508 in Q1 2026. 43 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Root Financial Partners reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 14 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $508.
  • Root Financial Partners first reported a position in Crinetics Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Crinetics Pharmaceuticals position peaked at $508 in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.